| Q36507182 | 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder |
| Q35401301 | 3D pattern of brain atrophy in HIV/AIDS visualized using tensor-based morphometry |
| Q42743771 | 4-Aminopyridine improves spatial memory in a murine model of HIV-1 encephalitis |
| Q33629205 | A High Prevalence Rate of a Positive Screen for Cognitive Impairment in Patients With Human Immunodeficiency Virus Attending an Irish Clinic |
| Q64084696 | A Naturally Occurring Polymorphism in the HIV-1 Tat Basic Domain Inhibits Uptake by Bystander Cells and Leads to Reduced Neuroinflammation |
| Q38087942 | A case of possible darunavir/ritonavir-induced peripheral neuropathy: case description and review of the literature |
| Q37463446 | A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects |
| Q28469254 | A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain |
| Q37829628 | A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: viral latency in the periphery and the central nervous system |
| Q34756259 | AIDS related opportunistic infections, going but not gone |
| Q57003024 | AIDS-associated Cryptococcus infection before and after the highly active antiretroviral therapy era: emerging management problems |
| Q30351230 | AIDS-associated progressive multifocal leukoencephalopathy : current management strategies. |
| Q37972113 | Accelerated aging and human immunodeficiency virus infection: emerging challenges of growing older in the era of successful antiretroviral therapy |
| Q45710953 | Acute Meningoencephalitis in Chronic Human Immunodeficiency Virus (HIV) Infection: Putative Central Nervous System Escape of HIV Replication |
| Q36584311 | Acute kidney injury and inflammatory immune reconstitution syndrome in mixed genotype (A/E) hepatitis B virus co-infection in HIV-associated lymphoma |
| Q37260795 | Adaptive evolution of simian immunodeficiency viruses isolated from 2 conventional-progressor macaques with encephalitis |
| Q30452291 | Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge |
| Q30241037 | Alarmins and central nervous system inflammation in HIV-associated neurological disorders |
| Q30712330 | Alcoholism and AIDS: magnetic resonance imaging approaches for detecting interactive neuropathology |
| Q48240154 | Anti-HIV drugs nevirapine and efavirenz affect anxiety-related behavior and cognitive performance in mice. |
| Q94601929 | Anti-HIV drugs promote β-amyloid deposition and impair learning and memory in BALB/c mice |
| Q35675045 | Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system |
| Q36635673 | Antiretroviral neurotoxicity |
| Q33980117 | Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions |
| Q36853897 | Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program |
| Q24676501 | Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration |
| Q44942423 | Brain aging in acquired immunodeficiency syndrome: increased ubiquitin-protein conjugate is correlated with decreased synaptic protein but not amyloid plaque accumulation |
| Q36104280 | Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance. |
| Q36282344 | Brain structural and functional recovery following initiation of combination antiretroviral therapy |
| Q37600700 | CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. |
| Q42925116 | Carbosilane dendrimers to transfect human astrocytes with small interfering RNA targeting human immunodeficiency virus |
| Q36128333 | Care of the human immunodeficiency virus-infected menopausal woman |
| Q48919955 | Cell death mechanisms in HIV-associated dementia: the involvement of syncytia |
| Q33987022 | Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus |
| Q45722309 | Central nervous system correlates of behavioral deficits following simian immunodeficiency virus infection |
| Q34799534 | Central nervous system disorders after starting antiretroviral therapy in South Africa |
| Q35126422 | Changing patterns in the neuropathogenesis of HIV during the HAART era. |
| Q82028949 | Chapter 42 Specific painful neuropathies |
| Q59351775 | Chronic Viral Neuroinflammation: Speculation on Underlying Mechanisms |
| Q35012478 | Circulating proviral HIV DNA and HIV-associated dementia |
| Q36940756 | Clade C HIV-1 isolates circulating in Southern Africa exhibit a greater frequency of dicysteine motif-containing Tat variants than those in Southeast Asia and cause increased neurovirulence. |
| Q46072201 | Clinical correlates of HIV-associated neurocognitive disorders in South Africa |
| Q30787775 | Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). |
| Q37029618 | Clinical features and preliminary studies of virological correlates of neurocognitive impairment among HIV-infected individuals in Nigeria |
| Q37300421 | Cocaine and HIV-1 interplay in CNS: cellular and molecular mechanisms |
| Q34421694 | Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms |
| Q22252615 | Cognitive neuropsychology of HIV-associated neurocognitive disorders |
| Q36712281 | Cognitive neurorehabilitation of HIV-associated neurocognitive disorders: a qualitative review and call to action |
| Q39930666 | Cognitive reserve and neuropsychological functioning in older HIV-infected people. |
| Q41989623 | Commonly prescribed antiretroviral therapy regimens and incidence of AIDS-defining neurological conditions |
| Q36294152 | Comparison of the Minimental State Examination Scale and the International HIV Dementia Scale in Assessing Cognitive Function in Nigerian HIV Patients on Antiretroviral Therapy |
| Q39140469 | Concordance Between Self-Report and Performance-Based Measures of Everyday Functioning in HIV-Associated Neurocognitive Disorders. |
| Q35037015 | Controversies in HIV-associated neurocognitive disorders |
| Q30478136 | Correlation of acute humoral response with brain virus burden and survival time in pig-tailed macaques infected with the neurovirulent simian immunodeficiency virus SIVsmmFGb |
| Q42445800 | Decreased neurotropism of nef long terminal repeat (nef/LTR)-deleted simian immunodeficiency virus |
| Q38801550 | Defining the roles for Vpr in HIV-1-associated neuropathogenesis. |
| Q37932423 | Delineating HIV-associated neurocognitive disorders using transgenic models: the neuropathogenic actions of Vpr. |
| Q36672574 | Detection of anti-tat antibodies in CSF of individuals with HIV-associated neurocognitive disorders |
| Q36367897 | Diagnostic accuracy of SPECT, PET, and MRS for primary central nervous system lymphoma in HIV patients: A systematic review and meta-analysis |
| Q40514849 | Diagnostic utility of the HIV dementia scale and the international HIV dementia scale in screening for HIV-associated neurocognitive disorders among Spanish-speaking adults |
| Q33712027 | Diffuse White Matter Signal Abnormalities on Magnetic Resonance Imaging Are Associated With Human Immunodeficiency Virus Type 1 Viral Escape in the Central Nervous System Among Patients With Neurological Symptoms |
| Q34784731 | Do common mental disorders decline over time in TB/HIV co-infected and HIV patients without TB who are on antiretroviral treatment? |
| Q36060119 | Does Older Age Confer an Increased Risk of Incident Neurocognitive Disorders Among Persons Living with HIV Disease? |
| Q34302241 | Dysregulation of macrophage-secreted cathepsin B contributes to HIV-1-linked neuronal apoptosis |
| Q42288366 | Effect of aging and human immunodeficiency virus infection on cognitive abilities |
| Q37176655 | Effects of antiretroviral therapy on cognitive impairment |
| Q35123216 | Effects of chronic HIV-1 Tat exposure in the CNS: heightened vulnerability of males versus females to changes in cell numbers, synaptic integrity, and behavior |
| Q28246676 | Effects of human immunodeficiency virus type 1 on astrocyte gene expression and function: potential role in neuropathogenesis |
| Q43869691 | Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity. |
| Q33754498 | Effects of vitamin A deficiency and opioids on parvalbumin + interneurons in the hippocampus of the HIV-1 transgenic rat. |
| Q44527255 | Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. |
| Q40042233 | Epidemiology of Peripheral Neuropathy: An Indian Perspective |
| Q40667677 | Establishment of an in vitro assay system mimicking human immunodeficiency virus type 1-induced neural cell death and evaluation of inhibitors thereof |
| Q34729027 | Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance. |
| Q30936809 | Evidence for predilection of macrophage infiltration patterns in the deeper midline and mesial temporal structures of the brain uniquely in patients with HIV-associated dementia |
| Q36796976 | Evolution of changes in cognitive function after the initiation of antiretroviral therapy |
| Q36302081 | Experimental and potential future therapeutic approaches for HIV-1 associated dementia targeting receptors for chemokines, glutamate and erythropoietin |
| Q37302953 | Expression of substance P, neurokinin-1 receptor and immune markers in the brains of individuals with HIV-associated neuropathology |
| Q40669121 | Facial Emotion Processing in Aviremic HIV-infected Adults |
| Q64255951 | Favorable Response to Mirtazapine in John Cunningham Virus-related Gray Matter Lesion in a Patient with Human Immunodeficiency Virus |
| Q32042586 | Focal neurological disease in patients with acquired immunodeficiency syndrome |
| Q83672856 | Follow-up magnetic resonance imaging findings in patients with progressive multifocal leukoencephalopathy: evaluation of long-term survivors under highly active antiretroviral therapy |
| Q34399011 | Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy |
| Q35957384 | Functional connectivity measured with magnetoencephalography identifies persons with HIV disease. |
| Q43227545 | GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicity |
| Q37418863 | Green Tea-EGCG reduces GFAP associated neuronal loss in HIV-1 Tat transgenic mice. |
| Q41712400 | HIV 1-associated neurocognitive disorder: current epidemiology, pathogenesis, diagnosis and management |
| Q57807608 | HIV Cerebrospinal Fluid Escape and Neurocognitive Pathology in the Era of Combined Antiretroviral Therapy: What Lies Beneath the Tip of the Iceberg in Sub-Saharan Africa? |
| Q53904491 | HIV Dementia. |
| Q36655162 | HIV and aging: implications for patient management |
| Q55344050 | HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz. |
| Q34563942 | HIV and the central nervous system. |
| Q88795213 | HIV disease and diabetes interact to affect brain white matter hyperintensities and cognition |
| Q35488817 | HIV leucoencephalopathy and TNFalpha expression in neurones |
| Q35063626 | HIV neuropathogenesis: a tight rope walk of innate immunity. |
| Q36722756 | HIV stroke risk: evidence and implications |
| Q34573511 | HIV, dementia and antiretroviral drugs: 30 years of an epidemic |
| Q43496324 | HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells |
| Q42097093 | HIV-1 Tat-mediated induction of CCL5 in astrocytes involves NF-κB, AP-1, C/EBPα and C/EBPγ transcription factors and JAK, PI3K/Akt and p38 MAPK signaling pathways |
| Q43251339 | HIV-1 clade-specific differences in the induction of neuropathogenesis |
| Q36633249 | HIV-1 encephalopathy among perinatally infected children: Neuropathogenesis and response to highly active antiretroviral therapy |
| Q53882620 | HIV-1 expression protects macrophages and microglia from apoptotic death. |
| Q36098879 | HIV-1 infection and AIDS: consequences for the central nervous system |
| Q30234305 | HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. |
| Q82182169 | HIV-TAT protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier |
| Q44251296 | HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium |
| Q38444808 | HIV-associated Neurocognitive Disorders and Antiretroviral Therapy: Current Concepts and Controversies |
| Q38441425 | HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. |
| Q53699104 | HIV-associated neurocognitive disorder in a KwaZulu-Natal HIV clinic: A prospective study. |
| Q34599414 | HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies |
| Q37720509 | HIV-associated neurocognitive disorders: recent advances in pathogenesis, biomarkers, and treatment. |
| Q37899895 | HIV-related neurocognitive impairment--a review |
| Q48499492 | High level HIV-1 DNA concentrations in brain tissues differentiate patients with post-HAART AIDS dementia complex or cardiovascular disease from those with AIDS. |
| Q34406750 | Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort |
| Q42439875 | Hippocampal synaptic dysfunction in a murine model of human immunodeficiency virus type 1 encephalitis |
| Q37416015 | Host and viral factors influencing the pathogenesis of HIV-associated neurocognitive disorders |
| Q40529504 | Host genetic polymorphisms in human immunodeficiency virus-related neurologic disease |
| Q44775961 | Human immunodeficiency virus type 1 Tat and methamphetamine affect the release and activation of matrix-degrading proteinases |
| Q35123435 | Human immunodeficiency virus type 1 infection of human brain-derived progenitor cells |
| Q34366008 | Human immunodeficiency virus-1 evolutionary patterns associated with pathogenic processes in the brain |
| Q35112016 | Human immunodeficiency virus-associated dementia: an evolving disease |
| Q35805647 | Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. |
| Q36866613 | Impact of HIV and aging on neuropsychological function |
| Q36763762 | Impact of age on markers of HIV-1 disease |
| Q34033558 | Impact of short-term combined antiretroviral therapy on brain virus burden in simian immunodeficiency virus-infected and CD8+ lymphocyte-depleted rhesus macaques |
| Q37801927 | Implications of efavirenz for neuropsychiatry: a review. |
| Q37659348 | Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect. |
| Q42871093 | Improved survival with combined chemo-radiotherapy in primary central nervous system lymphoma |
| Q40044096 | Incidence, clinical presentation, and outcome of HIV-1-associated cryptococcal meningitis during the highly active antiretroviral therapy era: a nationwide cohort study |
| Q34100209 | Incident neuropathy in HIV-infected patients on HAART |
| Q43586132 | Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia |
| Q40548756 | Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines |
| Q37073680 | Issues in co-morbid severe mental illnesses in HIV infected individuals |
| Q34193503 | Lessons learned developing a diagnostic tool for HIV-associated dementia feasible to implement in resource-limited settings: pilot testing in Kenya |
| Q58322056 | Leucoencefalopatía multifocal progresiva: desde el origen a 2008 |
| Q45673013 | Levels of human immunodeficiency virus type 1 (HIV-1) replication in macrophages determines the severity of murine HIV-1 encephalitis. |
| Q59341830 | Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance |
| Q34590964 | Longitudinal analysis of monocyte/macrophage infection in simian immunodeficiency virus-infected, CD8+ T-cell-depleted macaques that develop lentiviral encephalitis |
| Q40113932 | Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. |
| Q36659583 | Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons |
| Q37874123 | Lymphoproliferative Lesions in the Setting of HIV Infection: A Five-Year Retrospective Case Series and Review |
| Q39521282 | Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. |
| Q35098372 | Macrophage/microglial accumulation and proliferating cell nuclear antigen expression in the central nervous system in human immunodeficiency virus encephalopathy |
| Q36166123 | Mechanisms of the blood-brain barrier disruption in HIV-1 infection |
| Q34349192 | Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice |
| Q44747866 | Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons |
| Q39914267 | Methods to study monocyte migration induced by HIV-infected cells |
| Q34988471 | Micro-structural brain alterations in aviremic HIV+ patients with minor neurocognitive disorders: a multi-contrast study at high field |
| Q34963796 | Microglia in human immunodeficiency virus-associated neurodegeneration. |
| Q44158588 | Mixed lineage kinase 3 mediates gp120IIIB-induced neurotoxicity |
| Q33629698 | Molecular diagnosis of central nervous system opportunistic infections and mortality in HIV-infected adults in Central China |
| Q37273721 | Molecular mechanism(s) involved in the synergistic induction of CXCL10 by human immunodeficiency virus type 1 Tat and interferon-gamma in macrophages |
| Q28270413 | Monoclonal antibodies and progressive multifocal leukoencephalopathy |
| Q28751900 | Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate studies |
| Q36991666 | Monocyte/macrophages and their role in HIV neuropathogenesis |
| Q36384046 | Multivariable analysis to determine if HIV-1 Tat dicysteine motif is associated with neurodevelopmental delay in HIV-infected children in Malawi |
| Q26770401 | Natural Products as Anti-HIV Agents and Role in HIV-Associated Neurocognitive Disorders (HAND): A Brief Overview |
| Q35592605 | Neuro-ophthalmological disorders in HIV infected subjects with neurological manifestations |
| Q46272650 | NeuroAIDS in West Africa: a full circle. |
| Q30445058 | Neurobehavioral alterations in HIV-1 transgenic rats: evidence for dopaminergic dysfunction |
| Q35033471 | Neurocognitive impairment associated with predominantly early stage HIV infection in Abuja, Nigeria |
| Q82029714 | Neuroepidemiology of HIV/AIDS |
| Q35065220 | Neurologic aspects of HIV infection in infants and children: therapeutic approaches and outcome |
| Q36475300 | Neurologic disorders incidence in HIV+ vs HIV- men: Multicenter AIDS Cohort Study, 1996-2011. |
| Q36450742 | Neurological complications in AIDS patients receiving HAART: a 2-year retrospective study |
| Q35938577 | Neurological complications in AIDS patients: the 1-year retrospective study in Chiang Mai University, Thailand |
| Q41067770 | Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study |
| Q58855603 | Neurological disease in HIV-infected patients in the era of highly active antiretroviral treatment: a Brazilian experience |
| Q47586850 | Neurological opportunistic infections and neurological immune reconstitution syndrome: impact of one decade of highly active antiretroviral treatment in a tertiary hospital |
| Q37721505 | Neuronal Stress and Injury Caused by HIV-1, cART and Drug Abuse: Converging Contributions to HAND. |
| Q35098067 | Neuronal apoptosis is mediated by CXCL10 overexpression in simian human immunodeficiency virus encephalitis |
| Q44438229 | Neuronal injury regulates fractalkine: relevance for HIV-1 associated dementia |
| Q82029838 | Neuropharmacology of HIV/AIDS |
| Q33587971 | Neuroprotective activities of CEP-1347 in models of neuroAIDS. |
| Q42451198 | Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. |
| Q39363961 | Neuropsychiatric Aspects of Infectious Diseases: An Update |
| Q33868874 | Neuropsychiatric manifestations of HIV infection and AIDS |
| Q30389107 | Neuropsychological Dysfunction among HIV Infected Drug Abusers |
| Q37213350 | Neuropsychological assessment of HIV-infected populations in international settings |
| Q61716548 | Neuropsychological evaluation and follow up in jcv- and non-jcv-related leukoencephalopathies in HIV infection |
| Q44203427 | Neurotoxic effects of the human immunodeficiency virus type-1 transcription factor Tat require function of a polyamine sensitive-site on the N-methyl-D-aspartate receptor |
| Q36856162 | Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS |
| Q28246161 | No health without mental health |
| Q33533941 | Normative scores for a brief neuropsychological battery for the detection of HIV-associated neurocognitive disorder (HAND) among South Africans |
| Q34761828 | Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis |
| Q35071456 | Nucleoside analogues and neuropathy in the era of HAART. |
| Q44189447 | Ophthalmic manifestations of immune reconstitution inflammatory syndrome associated with Cryptococcus neoformans |
| Q30824043 | Opportunistic infections of the CNS in patients with AIDS: diagnosis and management |
| Q82029809 | Other opportunistic infections of the central nervous system in AIDS |
| Q36996124 | Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy |
| Q37695319 | PPAR agonist-mediated protection against HIV Tat-induced cerebrovascular toxicity is enhanced in MMP-9-deficient mice |
| Q34223078 | Pathways to neuronal injury and apoptosis in HIV-associated dementia. |
| Q37035634 | Peripheral blood HIV DNA is associated with atrophy of cerebellar and subcortical gray matter |
| Q35384460 | Peripheral neuropathy in HIV: prevalence and risk factors |
| Q34444007 | Perspective on HIV infection and aging: emerging research on the horizon |
| Q35175447 | Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection |
| Q37275841 | Platelet-derived growth factor protects neurons against gp120-mediated toxicity |
| Q36187139 | Population-based Incidence and Survival for Primary Central Nervous System Lymphoma in Korea, 1999-2009. |
| Q35699016 | Potentiation of Excitotoxicity in HIV-1 Associated Dementia and the Significance of Glutaminase |
| Q34162407 | PrPC, the Cellular Isoform of the Human Prion Protein, Is a Novel Biomarker of HIV-Associated Neurocognitive Impairment and Mediates Neuroinflammation |
| Q30451688 | Prepulse inhibition in HIV-associated neurocognitive disorders |
| Q39724313 | Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort |
| Q36645145 | Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study |
| Q34295513 | Prevalence of abnormalities in vestibular function and balance among HIV-seropositive and HIV-seronegative women and men |
| Q45410707 | Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment |
| Q43439053 | Prevention of cryptococcosis in HIV-infected patients with limited access to highly active antiretroviral therapy: evidence for primary azole prophylaxis |
| Q36616443 | Prevention, Rehabilitation, and Mitigation Strategies of Cognitive Deficits in Aging with HIV: Implications for Practice and Research |
| Q79495963 | Primary CNS lymphoma |
| Q33279538 | Primary CNS lymphoma in azathioprine therapy for autoimmune diseases: review of the literature and case report |
| Q80190988 | Primary central nervous system lymphoma |
| Q34540563 | Progress in clinical neurosciences: The neuropathogenesis of HIV infection: host-virus interaction and the impact of therapy. |
| Q30332766 | Progressive Multifocal Leukoencephalopathy in Acquired Immunodeficiency Syndrome: Explaining the High Incidence and Disproportionate Frequency of the Illness Relative to Other Immunosuppressive Conditions |
| Q26776236 | Progressive multifocal leukoencephalopathy: current treatment options and future perspectives |
| Q45722307 | Ramified feline microglia selects for distinct variants of feline immunodeficiency virus during early central nervous system infection |
| Q35627384 | Recent clinical history and cognitive dysfunction for attention and executive function among human immunodeficiency virus-infected patients |
| Q44532346 | Reduced expression of glutamate transporter EAAT2 and impaired glutamate transport in human primary astrocytes exposed to HIV-1 or gp120. |
| Q36142331 | Regional cortical thinning associated with detectable levels of HIV DNA. |
| Q37531674 | Relationships among neurocognitive status, medication adherence measured by pharmacy refill records, and virologic suppression in HIV-infected persons |
| Q40264010 | Reward, attention, and HIV-related risk in HIV+ individuals |
| Q59350870 | Risk Factors and Pathogenesis of HIV-Associated Neurocognitive Disorder: The Role of Host Genetics |
| Q44746049 | Risk modifiers for peripheral sensory neuropathy in HIV infection/AIDS. |
| Q35901271 | Role of Sigma Receptor in Cocaine-Mediated Induction of Glial Fibrillary Acidic Protein: Implications for HAND |
| Q37175209 | Roles of MCP-1 in development of HIV-dementia |
| Q73255202 | Roundtable Report: Importance of Antiretroviral Drug Concentrations in Sanctuary Sites and Viral Reservoirs |
| Q35533317 | Screening for HIV-associated dementia in South Africa: potentials and pitfalls of task-shifting |
| Q36846855 | Screening for Neurocognitive Impairment in HIV-Infected Individuals at First Contact after HIV Diagnosis: The Experience of a Large Clinical Center in Northern Italy |
| Q39398131 | Screening for human immunodeficiency virus (HIV) dementia in an HIV clade C-infected population in India |
| Q41891032 | Sedimentation velocity studies of the high-molecular weight aggregates of the HIV gp41 ectodomain |
| Q46980169 | Severe aseptic leucoencephalopathy. Manifested as immune reconstitution inflammatory syndrome in Caucasian and African patients |
| Q42807041 | Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy |
| Q45415196 | Simian immunodeficiency virus envelope compartmentalizes in brain regions independent of neuropathology |
| Q33893665 | Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA |
| Q37198955 | Simplification of the research diagnosis of HIV-associated sensory neuropathy |
| Q28729739 | Soluble and cell-associated insulin receptor dysfunction correlates with severity of HAND in HIV-infected women |
| Q33495226 | Synaptic proteins linked to HIV-1 infection and immunoproteasome induction: proteomic analysis of human synaptosomes |
| Q54982714 | Temporal/compartmental changes in viral RNA and neuronal injury in a primate model of NeuroAIDS. |
| Q34051545 | The Montreal cognitive assessment to screen for cognitive impairment in HIV patients older than 60 years |
| Q30797688 | The changing pattern of HIV neuropathology in the HAART era. |
| Q35883236 | The effects of antiretroviral treatment initiation on cognition in HIV-infected individuals with advanced disease in Pune, India |
| Q90140528 | The far-reaching HAND of cART: cART effects on astrocytes |
| Q34134168 | The gp120 protein is a second determinant of decreased neurovirulence of Indian HIV-1C isolates compared to southern African HIV-1C isolates |
| Q82029739 | The neuropathogenesis of HIV-1 infection |
| Q35758347 | The psychosocial and health care needs of HIV-positive people in the United Kingdom: a review |
| Q34787585 | The role of medical imaging in defining CNS abnormalities associated with HIV-infection and opportunistic infections |
| Q36302070 | The signaling and apoptotic effects of TNF-related apoptosis-inducing ligand in HIV-1 associated dementia |
| Q36600970 | Therapy Insight: CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome |
| Q37781306 | Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction |
| Q33348210 | Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy |
| Q51040063 | Toxoplasmic encephalitis in AIDS-patients before and after the introduction of highly active antiretroviral therapy (HAART). |
| Q44678351 | Transcranial sonography of the third ventricle and cognitive dysfunction in HIV patients |
| Q39077816 | Treating HIV Infection in the Central Nervous System |
| Q33717183 | Trends in AIDS-defining opportunistic illnesses incidence over 25 years in Rio de Janeiro, Brazil |
| Q48915551 | Trends related to aging and co-occurring disorders in HIV-infected drug users |
| Q34787071 | Understanding pathogenesis and treatment of HIV dementia: a role for magnetic resonance? |
| Q33672408 | Unmasking of PML by HAART: unusual clinical features and the role of IRIS |
| Q30504584 | Up-regulation of the neuronal nicotinic receptor α7 by HIV glycoprotein 120: potential implications for HIV-associated neurocognitive disorder |
| Q48687135 | Using gene delivery to protect HIV-susceptible CNS cells: inhibiting HIV replication in microglia. |
| Q40705620 | Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS. |
| Q35050070 | Verbal memory declines more rapidly with age in HIV infected versus uninfected adults |
| Q38217388 | Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND) |
| Q46519431 | Visual attention deficits are associated with driving accidents in cognitively-impaired HIV-infected individuals |
| Q42167969 | Voriconazole proves effective in long-term treatment of a cerebral cryptococcoma in a chronic nephropathic HIV-negative patient, after fluconazole failure |
| Q86704966 | [Cerebral Changes in the Morphometrics of HIV Patients] |
| Q81741351 | [Infections of the central nervous system in the immuno-compromised] |